Evidence map›Paper›PMID 38496611›Full record

ArticleResearch square2024

An interactive atlas of genomic, proteomic, and metabolomic biomarkers promotes the potential of proteins to predict complex diseases.

Mikael Benson, Martin Smelik, Xinxiu Li, Joseph Loscalzo, Oleg Sysoev, Firoj Mahmud, Dina Mansour Aly, Yelin Zhao

Open access · greenAbstract readPreprint
In one paragraph

Article in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Mikael BensonKarolinska Institute.
Martin SmelikKarolinska Institute.
Xinxiu LiKarolinska Institute.
Joseph LoscalzoBrigham and Women's Hospital.
Oleg SysoevLinköping University.
Firoj MahmudKarolinska Institute.
Dina Mansour AlyKarolinska Institute.
Yelin ZhaoKarolinska Institute.
Karolinska Institutet · SEBrigham and Women's Hospital · USLinköping University · SE

Funding

L-2-Hydroxyglutarate and Metabolic Remodeling in HypoxiaR01HL155107 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI Joseph Loscalzo · 2021 to 2026
$4.1M
Personalized protein-protein interactomes and precision medicine in pulmonary arterial hypertensionR01HL155096 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI MARON, BRADLEY · 2021 to 2024
$1.6M
NHLBI NIH HHS R01 HL155096NHLBI NIH HHS R01 HL155107
6 · The paper itself

Abstract

Multiomics analyses have identified multiple potential biomarkers of the incidence and prevalence of complex diseases. However, it is not known which type of biomarker is optimal for clinical purposes. Here, we make a systematic comparison of 90 million genetic variants, 1,453 proteins, and 325 metabolites from 500,000 individuals with complex diseases from the UK Biobank. A machine learning pipeline consisting of data cleaning, data imputation, feature selection, and model training using cross-validation and comparison of the results on holdout test sets showed that proteins were most predictive, followed by metabolites, and genetic variants. Only five proteins per disease resulted in median (min-max) areas under the receiver operating characteristic curves for incidence of 0.79 (0.65-0.86) and 0.84 (0.70-0.91) for prevalence. In summary, our work suggests the potential of predicting complex diseases based on a limited number of proteins. We provide an interactive atlas (macd.shinyapps.io/ShinyApp/) to find genomic, proteomic, or metabolomic biomarkers for different complex diseases.

Identifiers

PMID38496611
PMCPMC10942575
OpenAlexW4392454516

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.